Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response
JCO Clinical Cancer Informatics · 2025-03 · (9)
DOI: 10.1200/cci-24-00160 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025-03. Verfasst von Aaron Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematics, University of Minnesota, Twin Cities, MN. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NSF.
Abstract (Originalsprache)
PURPOSE Circulating tumor DNA (ctDNA) assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design of ctDNA biomarkers of therapy response that incorporate variations in ctDNA dynamics driven by specific treatment mechanisms. These biomarkers are based on novel proposals for ctDNA sampling protocols, consisting of frequent sampling within a compact time window surrounding therapy initiation—which we hypothesize to hold valuable prognostic information on longer-term treatment response. METHODS We develop mathematical models of ctDNA kinetics driven by tumor response to several therapy classes and use them to simulate randomized virtual patient cohorts to test candidate biomarkers. RESULTS Using this approach, we propose specific biomarkers, on the basis of ctDNA longitudinal features, for targeted therapy and radiation therapy. We evaluate and demonstrate the efficacy of these biomarkers in predicting treatment response within a randomized virtual patient cohort data set. CONCLUSION This study highlights a need for tailoring ctDNA sampling protocols and interpretation methodology to specific biologic mechanisms of therapy response, and it provides a novel modeling and simulation framework for doing so. In addition, it highlights the potential of ctDNA assays for making early, rapid predictions of treatment response within the first days or weeks of treatment and generates hypotheses for further clinical testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Mathematics, University of Minnesota, Twin Cities, MN.
- Masonic Cancer Center, University of Minnesota, Twin Cities, MN.
- Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Twin Cities, MN.
- Department of Industrial and Systems Engineering, University of Minnesota, Twin Cities, MN.
ORCID-Profile: Aaron Li, Emil Lou, Jasmine Foo
Förderung
- NSF
Zitieren
APA
Li, A., Lou, E., Leder, K., & Foo, J. (2025). Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00160
Vancouver
Li A, Lou E, Leder K, Foo J. Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00160
BibTeX
@article{Li2025,
author = {Li, Aaron and Lou, Emil and Leder, Kevin and Foo, Jasmine},
title = {Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
number = {9},
doi = {10.1200/cci-24-00160}
}
EUVIMED